Last reviewed · How we verify
Test-Brinzolamide 1% Ophthalmic suspension
Test-Brinzolamide 1% Ophthalmic suspension is a Carbonic anhydrase inhibitor Small molecule drug developed by Actavis Inc.. It is currently in Phase 3 development for Treatment of ocular hypertension or glaucoma.
Test-Brinzolamide 1% Ophthalmic suspension works by reducing intraocular pressure by increasing the outflow of aqueous humor.
Test-Brinzolamide 1% Ophthalmic suspension works by reducing intraocular pressure by increasing the outflow of aqueous humor. Used for Treatment of ocular hypertension or glaucoma.
At a glance
| Generic name | Test-Brinzolamide 1% Ophthalmic suspension |
|---|---|
| Sponsor | Actavis Inc. |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase II |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It does this by inhibiting the carbonic anhydrase enzyme in the ciliary epithelium, which leads to a decrease in aqueous humor production and an increase in its outflow. This results in a reduction in intraocular pressure, which is beneficial for patients with glaucoma or ocular hypertension.
Approved indications
- Treatment of ocular hypertension or glaucoma
Common side effects
- Blepharitis
- Eye irritation
- Headache
Key clinical trials
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Test-Brinzolamide 1% Ophthalmic suspension CI brief — competitive landscape report
- Test-Brinzolamide 1% Ophthalmic suspension updates RSS · CI watch RSS
- Actavis Inc. portfolio CI
Frequently asked questions about Test-Brinzolamide 1% Ophthalmic suspension
What is Test-Brinzolamide 1% Ophthalmic suspension?
How does Test-Brinzolamide 1% Ophthalmic suspension work?
What is Test-Brinzolamide 1% Ophthalmic suspension used for?
Who makes Test-Brinzolamide 1% Ophthalmic suspension?
What drug class is Test-Brinzolamide 1% Ophthalmic suspension in?
What development phase is Test-Brinzolamide 1% Ophthalmic suspension in?
What are the side effects of Test-Brinzolamide 1% Ophthalmic suspension?
What does Test-Brinzolamide 1% Ophthalmic suspension target?
Related
- Drug class: All Carbonic anhydrase inhibitor drugs
- Target: All drugs targeting Carbonic anhydrase II
- Manufacturer: Actavis Inc. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of ocular hypertension or glaucoma
- Compare: Test-Brinzolamide 1% Ophthalmic suspension vs similar drugs
- Pricing: Test-Brinzolamide 1% Ophthalmic suspension cost, discount & access